3-(3,4,5-Trimethoxyphenyl)-1-oxo-2-propene: A novel pharmacophore displaying potent multidrug resistance reversal and selective cytotoxicity

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 10, 2007, Pages 3373-3380

  Das, Umashankar ^a   Kawase, Masami ^b   Sakagami, Hiroshi ^c   Ideo, Atsushi ^c   Shimada, Jun ^c   Molnár, Joseph ^d   Baráth, Zoltán ^d   Bata, Zsuzsanna ^d   Dimmock, Jonathan R ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b MATSUYAMA UNIVERSITY   (Japan)

^c MEIKAI UNIVERSITY SCHOOL OF DENTISTRY   (Japan)

^d UNIVERSITY OF SZEGED   (Hungary)

Author keywords

3 (3,4,5 Trimethoxyphenyl) 2 propenoyl pharmacophore; Cytotoxicity; Multidrug resistance; Unsaturated ketones

Indexed keywords

2,5 (3,4,5 TRIMETHOXYPHENYLMETHYLENE)CYCLOPENTANONE; 3 (3,4,5 TRIMETHOXYPHENYL) 1 OXO 2 PROPENE; 3 (3,4,5 TRIMETHOXYPHENYL) 2 PROPENOYL DERIVATIVE; 6 (4 NITROPHENYLMETHYLENE) 2 (3,4,5 TRIMETHOXYPHENYLMETHYLENE)CYCLOHEXANONE; ALICYCLIC COMPOUND; ANTINEOPLASTIC AGENT; CASPASE 3; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; CANCER CELL; CELL STRAIN HL 60; CYTOTOXICITY; ENZYME ACTIVATION; MULTIDRUG RESISTANCE; PHARMACOPHORE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; HL-60 CELLS; HUMANS; INDICATORS AND REAGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; PROPANE; SPECTROMETRY, FLUORESCENCE;

EID: 34047162444     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.03.022     Document Type: Article

References (28)

1. Millward M.J., Cantwell B.M., Munro N.C., Robinson A., Corris P.A., and Harris A.L. Br. J. Cancer 67 (1993) 1031-1035
2. Budd G.T., Bukowski R.M., Lichtin A., Bauer L., Van Kirk P., and Ganapathi R. Invest. New Drugs 11 (1993) 75-79
3. Miller T.P., Chase E.M., Dorr R., Dalton W.S., Lam K.S., and Salmon S.E. Anticancer Drugs 9 (1998) 135-140
4. Peck R.A., Hewett J., Harding M.W., Wang Y.M., Chaturvedi P.R., Bhatnagar A., Ziessman H., Atkins F., Hawkins M.J., and Vincent T. J. Clin. Oncol. 19 (2001) 3130-3141
5. Dimmock J.R., Das U., Gul H.I., Kawase M., Sakagami H., Baráth Z., Ocsovsky I., and Molnár J. Bioorg. Med. Chem. Lett. 15 (2005) 1633-1636
6. Das U., Gul H.I., Alcorn J., Shrivastav A., George T., Sharma R.K., Nienaber K.H., De Clercq E., Balzarini J., Kawase M., Kan N., Tanaka T., Tani S., Werbovetz K.A., Yakovich A.J., Manavathu E.K., Stables J.P., and Dimmock J.R. Eur. J. Med. Chem. 41 (2006) 577-585
7. Low L.K. In: Delgado J.N., and Remers W.A. (Eds). Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry. 10th ed. (1998), Lippincott-Raven, Publishers, Philadelphia, PA 86
8. Williams D.A. In: Foye W.O., Lemke T.L., and Williams D.A. (Eds). Principles of Medicinal Chemistry. 4th ed. (1995), Williams and Wilkins, Baltimore, MD 111
9. Goldstein A., Aronow L., and Kalman S.M. Principles of Drug Action. 2nd ed. (1974), John Wiley and Sons, New York, NY pp. 682-685
10. Hassner A., and Mead T.C. Tetrahedron 20 (1964) 2201-2210
11. Dimmock J.R., Padmanilayam M.P., Zello G.A., Nienaber K.H., Allen T.M., Santos C.L., De Clercq E., Balzarini J., Manavathu E.K., and Stables J.P. Eur. J. Med. Chem. 38 (2003) 169-177
12. Dimmock J.R., Chamankhah M., Das U., Zello G.A., Quail J.W., Yang J., Nienaber K.H., Sharma R.K., Selvakumar P., Balzarini J., De Clercq E., and Stables J.P. J. Enzyme Inhib. Med. Chem. 19 (2004) 1-10
13. Kevill D.N., Weiler E.D., and Cromwell N.H. J. Org. Chem. 29 (1964) 1276-1278
14. Dimmock J.R., Kandepu N.M., Hetherington M., Quail J.W., Pugazhenthi U., Sudom A.M., Chamankhah M., Rose P., Pass E., Allen T.M., Halleran S., Szydlowski J., Mutus B., Tannous M., Manavathu E.K., Myers T.G., De Clercq E., and Balzarini J. J. Med. Chem. 41 (1998) 1014-1026
15. Quail J.W., Das U., and Dimmock J.R. Acta Cryst. 61 (2005) 1150-1152
16. Dimmock J.R., Jha A., Zello G.A., Allen T.M., Santos C.L., Balzarini J., De Clercq E., Manavathu E.K., and Stables J.P. Pharmazie 58 (2003) 227-232
17. Jha A., Zhao J., Cameron T.S., De Clercq E., Balzarini J., Manavathu E.K., and Stables J.P. Lett. Drug Des. Discov. 3 (2006) 304-310
18. Molnár J., Gyémánt N., Tanaka M., Hohlmann J., Bergmann-Leitner E., Molnár P., Deli J., Didziazapetris R., and Ferreira M.J. Curr. Pharm. Des. 12 (2006) 287-311
19. Tsurusawa M., Saeki K., and Fujimoto T. Int. J. Hematol. 66 (1997) 79-88
20. Ding G., Liu F., Yang T., Jiang Y., Fu H., and Zhao Y. Bioorg. Med. Chem. 14 (2006) 3766-3774
21. Du A., Zhao B., Yin D., Zhang S., and Miao J. Bioorg. Med. Chem. Lett. 16 (2006) 81-83
22. Friedmann E. J. Prakt. Chem. 146 (1936) 65
23. Engi H., Gyémánt N., Lóránd T., Lévai A., Ocsovszki I., and Molnár J. In Vivo 20 (2006) 119-124
24. Cornwell M.M., Pastan I., and Gottesmann M. J. Biol. Chem. 262 (1987) 2166-2170
25. Momoi K., Sugita Y., Ishihara J., Satoh K., Kikuchi H., Hashimoto K., Yokoe I., Nishikawa H., Fujisawa S., and Sakagami H. In Vivo 19 (2005) 157-164
26. Takeuchi R., Hoshijima H., Onuki N., Nagasaka H., Chowdbury S.A., Kawase M., and Sakagami H. Anticancer Res. 25 (2005) 4037-4042
27. Nakayachi T., Yasumoto E., Nakano K., Morshed S.R.M., Hashimoto K., Kikuchi H., Nishikawa H., Kawase M., and Sakagami H. Anticancer Res. 24 (2004) 732-742
28. Kawase M., Sakagami H., Motohashi N., Hauer H., Chatterjee S.S., Spengler G., Vigyikanne A.V., Molnár A., and Molnár J. In Vivo 19 (2005) 705-712